Circulating tumor cells as a potential biomarker in diagnosis of lung cancer: a systematic review and meta-analysis

2016 ◽  
Vol 12 (2) ◽  
pp. 639-645 ◽  
Author(s):  
Huang Huang ◽  
Yan Shi ◽  
Jietao Huang ◽  
Xiaohui Wang ◽  
Rui Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Meta Analysis ◽  
Potential Biomarker ◽  
Diagnosis Of Lung Cancer

scholarly journals Meta-analysis of Circulating Tumor Cells as a Prognostic Marker in Lung Cancer

2012 ◽  
Vol 13 (4) ◽  
pp. 1137-1144 ◽  
Author(s):  
Xue-Lei Ma ◽  
Zhi-Lan Xiao ◽  
Lei Liu ◽  
Xiao-Xiao Liu ◽  
Wen Nie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Prognostic Marker ◽  
Meta Analysis

scholarly journals Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer

2019 ◽  
Vol 8 (8) ◽  
pp. 3782-3792 ◽  
Author(s):  
Yang Li ◽  
Xudong Tian ◽  
Lei Gao ◽  
Xiaohong Jiang ◽  
Rao Fu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Tumor Markers ◽  
Clinical Significance ◽  
Diagnosis Of Lung Cancer

scholarly journals Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Sha-Sha Jiang ◽  
Bo Deng ◽  
Yong-Geng Feng ◽  
Kai Qian ◽  
Qun-You Tan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Initial Treatment ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
System Review

Abstract Background Our study aimed to verify the prognostic value of circulating tumor cells (CTCs) prior to initial treatment on survival of non-small cell lung cancer (NSCLC) by using meta-analysis and system review of published studies. Materials and methods The PubMed, EMBASE and Cochrane Library were searched, respectively, to identify all studies that addressed the issues of CTCs prior to initial treatment and progression-free survival (PFS) and overall survival (OS). Finally, ten citations were included for analysis and assessment of publication bias by using review manager 5.3 statistical software and STATA 15.0. Results Randomized model analyzing multivariate Cox Proportional Hazards Regression indicated that higher abundance of CTCs significantly predicts poorer prognosis of lung cancer cases basing both on PFS (Z = 2.31, P = 0.02) and OS of advanced cases (Z = 2.44, P = 0.01), and systematic study aslo indicated the similar results. Conclusion High CTCs prior to initial treatment can predict shorter PFS and OS in NSCLC, and further studies are warranted in the future.

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

2019 ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Likelihood Ratio ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Disease Free Survival ◽  
Negative Likelihood Ratio ◽  
Free Survival ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker

Abstract Background: Recently, a growing number of studies have reported the coorelation between miR-155 and the diagnosis and prognosis of lung cancer, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out the systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of lung cancer. Methods: A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and Web of Science. We screened all correlated literaters until December 1st, 2018. For the diagnosis analysis of miR-155 in lung cancer, sensitivity(SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the ROC curve (AUC) were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of lung cancer. For the prognosis analysis of miR-155 in lung cancer, the pooled HRs and 95% CIs of miR-155 for overall survival/disease free survival/progression-free survival (OS/DFS/PFS) were calculated. In addition, Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. Results: For the diagnostic analysis of miR-155 in lung cancer, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76-5.10), NLR was 0.23 (95% CI: 0.15-0.37), DOR was 15.99 (95% CI: 8.11-31.52) and AUC was 0.87 (95% CI: 0.84-0.90), indicating a significant value of miR-155 in the lung cancer detection. For the prognostic analysis of miR-155 in lung cancer, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66-2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82-1.97). Conclusions: The present meta-analysis demonstrated that miR-155 could be a potential biomarker for the detection of lung cancer but not an effective biomarker for predicting the outcomes of lung cancer. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of lung cancer.

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

2019 ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Likelihood Ratio ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Disease Free Survival ◽  
Negative Likelihood Ratio ◽  
Free Survival ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker

Abstract Background: Recently, a growing number of studies have reported the coorelation between miR-155 and the diagnosis and prognosis of lung cancer, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out the systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of lung cancer. Methods: A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and Web of Science. We screened all correlated literaters until December 1st, 2018. For the diagnosis analysis of miR-155 in lung cancer, sensitivity(SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the ROC curve (AUC) were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of lung cancer. For the prognosis analysis of miR-155 in lung cancer, the pooled HRs and 95% CIs of miR-155 for overall survival/disease free survival/progression-free survival (OS/DFS/PFS) were calculated. In addition, Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. Results: For the diagnostic analysis of miR-155 in lung cancer, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76-5.10), NLR was 0.23 (95% CI: 0.15-0.37), DOR was 15.99 (95% CI: 8.11-31.52) and AUC was 0.87 (95% CI: 0.84-0.90), indicating a significant value of miR-155 in the lung cancer detection. For the prognostic analysis of miR-155 in lung cancer, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66-2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82-1.97). Conclusions: The present meta-analysis demonstrated that miR-155 could be a potential biomarker for the detection of lung cancer but not an effective biomarker for predicting the outcomes of lung cancer. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of lung cancer.

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

2019 ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Bibliographic Databases ◽  
Diagnosis And Prognosis ◽  
Prognostic Analysis ◽  
Potential Biomarker ◽  
Keywords Lung Cancer ◽  
The Impact

Abstract Abstract Background: In recent years, several studies have investigated the impact of miR-155 on the diagnosis and prognosis of LCa, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out this systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of LCa. Methods: A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and other bibliographic databases. We screened all correlated literaters until December 1st, 2018. For the diagnostic value of miR-155 in LCa, SEN, SPE, PLR, NLR, DOR and AUC were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of LCa. Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. For the prognositic value of miR-155 in LCa, the pooled HRs and 95% CIs of miRNA-155 for OS and DFS/ PFS were calculated. Results: For the diagnosis analysis of miR-155 in LCa, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76-5.10), NLR was 0.23 (95% CI: 0.15-0.37), DOR was 15.99 (95% CI: 8.11-31.52) and AUC was 0.87 (95% CI: 0.84-0.90), indicating a significant value of miR-155 in the LCa detection. For the prognostic analysis of miR-155 in LCa, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66-2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82-1.97). Conclusions: This meta-analysis demonstrated that miR-155 could be used as a potential biomarker in the diagnosis of LCa but not an effective biomarker for predicting the prognosis of LCa. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of LCa. Keywords: lung cancer, miR-155, diagnosis, prognosis, biomarker

Sign in / Sign up

Export Citation Format

Share Document